NASDAQ:CRNX Crinetics Pharmaceuticals Q2 2026 Earnings Results & Report Crinetics Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 3, 2026. The company reported EPS of -$1.14 versus the -$1.18 consensus estimate, while revenue of $25.12 million topped the $14.84 million estimate by $10.28 million. Revenue increased 2,336.9% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 3, 2026TimeAfter Market ClosesConference Call4:00 PM ET Crinetics Pharmaceuticals EPS ResultsActual EPS-$1.14Consensus EPS -$1.18Beat/MissBeat by +$0.04One Year Ago EPS-$1.23EPS Beat Rate3 of last 8 quartersCrinetics Pharmaceuticals Revenue ResultsActual Revenue$25.12 millionExpected Revenue$14.84 millionBeat/MissBeat by +$10.28 millionYoY Revenue Growth+2,336.90%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Crinetics Pharmaceuticals Q2 2026 Earnings FAQ Did Crinetics Pharmaceuticals beat earnings estimates for Q2 2026? Crinetics Pharmaceuticals (NASDAQ:CRNX) reported earnings of -$1.14 per share for Q2 2026, beating the consensus estimate of -$1.18. The report was announced on Monday, August 3, 2026. What was Crinetics Pharmaceuticals' revenue for Q2 2026? Crinetics Pharmaceuticals reported revenue of $25.12 million for Q2 2026, against a consensus estimate of $14.84 million. Crinetics Pharmaceuticals Earnings HeadlinesCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P TMI IndexSeptember 3, 2026 | marketscreener.comMCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Pharmaceuticals Select Industry IndexSeptember 3, 2026 | marketscreener.comMVertex Pharmaceuticals Closes Crinetics Pharmaceuticals AcquisitionSeptember 1, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—CRNX, PSBQ, D, and NEEAugust 7, 2026 | globenewswire.comSee More Crinetics Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crinetics Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crinetics Pharmaceuticals and other key companies, straight to your email. Email Address About Crinetics PharmaceuticalsCrinetics Pharmaceuticals (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing orally delivered, small-molecule therapies for endocrine conditions and other hormone-related diseases. The company’s research is centered on medicines designed to act on peptide hormone receptors, with the goal of providing alternatives to injectable therapies. Crinetics’ lead product candidate is paltusotine, an oral, selective somatostatin receptor type 2 agonist being developed for the treatment of acromegaly, a rare disorder caused by excessive growth hormone production. The company is also developing atumelnant, formerly known as CRN04894, an oral adrenocorticotropic hormone receptor antagonist being investigated for conditions including congenital adrenal hyperplasia and Cushing’s disease. Founded in 2008 and headquartered in San Diego, California, Crinetics conducts research and clinical development activities intended to serve patients in the United States and international markets. The company’s leadership includes founder and Chief Executive Officer Scott Struthers, Ph.D., who has guided the organization’s focus on orally administered therapies for endocrine disorders.View Crinetics Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20Keysight Technologies: The Tollbooth on the Technology SuperhighwayGrowing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?Bargain Hunting: Why Off-Price Retail Is WinningZscaler Got a Boost From Palo Alto, But Now It Has to Deliver.If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.